# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0001829126-25-004961
**Filing Date:** 2025-7
**Character Count:** 12046
**Document Hash:** 7fddc54cc6933dea42458b697ca5b36b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-25-004961.hdr.sgml**: 20250709

**ACCESSION NUMBER**: 0001829126-25-004961

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250709

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250709

**DATE AS OF CHANGE**: 20250709

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55008
- **FILM NUMBER:** 251112349

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **July 9, 2025**

**<u>ZEO SCIENTIFIX, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55008** | **47-4180540** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3321 College Avenue, Suite 246<br> Davie, Florida** | **33314** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 963-7881</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), and unless otherwise indicated, the terms "**the Company**," "**ZEO**," "**we**," "**us**" and "**our**" refer to Zeo ScientifiX, Inc.

**Item 8.01 Other Events.**

On July 9, 2025, ZEO issued a press release announcing a new expansion initiative, including a new website and agency partnerships, to address expected biologics market demand following the July 1, 2025 effectiveness of a new Florida law which authorizes the use of non-FDA-approved stem cell therapies that are compliant with the new regulations for the treatment of certain defined conditions.

A copy of the press release is included as **Exhibit 99.1** to this Report.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits* 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated July 9, 2025](zeoscientifix_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: July 9, 2025 | **ZEO SCIENTIFIX, INC.** | **ZEO SCIENTIFIX, INC.** |
|  | By: | /s/ Ian T. Bothwell |
|  |  | Ian T. Bothwell<br> Interim Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida**

*ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law*

FORT LAUDERDALE – July 9, 2025 – ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB: ZEOX), a clinical-stage biopharmaceutical company pioneering the development of innovative biological therapeutics, is spearheading an expansion initiative aligned with the implementation of Florida's new SB-1768 stem cell law. With Florida now authorizing the use of non-FDA-approved stem cell therapies that are compliant with the new regulations for the treatment of certain defined conditions, ZEO is seeking to take advantage of the opportunity to set what it believes will be the industry standard through its product platform, new agency partnerships and educational initiatives.

**The Future of Regenerative Medicine is Now**

ZEO's turnkey product platform consists of a proprietary suite of ethically sourced biologics, developed and processed in a state-of-the-art FDA-registered, cGMP-compliant facility and physician education initiatives to assist Florida physicians in delivering regenerative care safely and compliantly under the new Florida guidelines. With an inventory of safe, regulatory-compliant biologics, a history of first-class research and competitive pricing, ZEO believes it is uniquely positioned to lead Florida's new era of accessibility and innovation in the biologics market.

"We believe that ZEO is entering into a new chapter of growth and expect additional states to join Florida in recognizing the therapeutic potential of regenerative biologics," said Ian Bothwell, interim chief executive officer of ZEO ScientifiX. "We're not just ready for this shift, we've built the product platform, partnerships and scientific roadmap to lead it."

With an expanding product pipeline, physician education initiatives and a strong compliance focus, ZEO is positioning itself as the go-to source for safe, effective and ethically developed regenerative therapies that have been legally approved.

**ZEO Launches New Website to Reflect Market Evolution**

 **<br> In conjunction with the July 1, 2025, effective date of the new Florida legislation, ZEO has unveiled a newly redesigned website at <u>www.zeoscientifix.com</u>. The new platform highlights the Company's commitment to education, compliance and long-term therapeutic innovation — offering streamlined access to clinical data, physician resources and product information.**

**Strategic Agency Partnerships Support National Brand Presence**

To further support this next phase of growth, ZEO ScientifiX has partnered with two key agencies:

●  **<u>Plus4 Public Relations</u>** , a national firm specializing in earned media, content development and strategic communications;

●  **<u>Small Circle</u>** , a full-service creative agency focused on brand identity, design and audience resonance.

ZEO believes that these partnerships will help them amplify their message and elevate their presence across emerging regenerative medicine markets in Florida and other states, when and where applicable.

**About ZEO ScientifiX, Inc.**

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is not just committed to maintaining pace with regulatory change — our goal is to set the standard. As a clinical-stage biopharmaceutical company focused on the development of biological therapeutic platforms, we believe that when physicians are educated, patients are better served — and innovation thrives. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and (b) Patient Pure X™ ("PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood, are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit <u>https://zeoscientifix.com</u>.

**Forward-Looking Statements**

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Florida Stem Cell Law will be beneficial to the Company or any initiatives related to this new law will increase our revenues and/or the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

**Contact Information**

Chloe Detrick

Plus4 Public Relations

chloe@plus4pr.com

SOURCE: ZEO ScientifiX, Inc.